Victrex (VTXPF) AI Stock Analysis
Victrex
(Other OTC:VTXPF)
No summary available
Victrex (VTXPF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $793.57M
- Dividend Yield
- 6.99%
- Average Volume (3M)
- 694
- Price to Earnings (P/E)
- -39.6
- Beta (1Y)
- 0.18
- Revenue Growth
- 3.74%
- EPS Growth
- -169.28%
- Country
- US
- Employees
- 1,169
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
Victrex Business Overview & Revenue Model
Company Description
Operating globally through its subsidiaries, Victrex plc is a specialized producer and distributor of polymer materials. The company organizes its business into two core divisions: Industrial and Medical. It concentrates on creating PEEK and PAEK pol...
Victrex Earnings Call Summary
The earnings call presented a mixed picture with notable achievements in volume growth and cash conversion, while facing significant challenges due to currency impacts, weaker medical spine performance, and losses from the China facility. The profit improvement plan and diversification in medical revenues are positive steps, but current financial challenges weigh heavily.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
In the call, Victrex provided guidance on various financial metrics for fiscal year 2025 and the outlook for 2026. The company reported a 12% increase in sales volume, reaching 4,164 tonnes, mainly driven by value-added resellers (VARs) and the Energy & Industrial sector. Despite the robust volume growth, underlying profit before tax (PBT) was impacted by an adverse currency effect of GBP 8 million, resulting in a 21% decrease to GBP 46.4 million. However, cash conversion was strong at 121%, benefiting from efficient working capital management. Capital expenditures (CapEx) saw a significant reduction, reflecting the conclusion of recent investment phases. For fiscal 2026, Victrex is targeting low to mid-single-digit volume growth and aims to achieve at least GBP 10 million in savings through a profit improvement plan. Gross margin for FY '26 is expected to be flat to slightly ahead, with the China manufacturing facility remaining a focus for operational improvements. The company will maintain its dividend and review its capital allocation policy, aiming to retain a strong balance sheet with a net debt-to-EBITDA range of 0.5x to 1x.
Victrex Peers Comparison
Overall Rating
GB:ELM73Outperform
GB:ZTF68Neutral
GB:CRDA66Neutral
GB:SYNT60Neutral
GB:ESNT53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | GBP 1.09B | 20.15 | 11.29% | 1.72% | -11.73% | ― | |
| 68Neutral | GBP 222.30M | 8.93 | 18.18% | 1.79% | 14.35% | 3370.14% | |
| 66Neutral | GBP 5.04B | 64.55 | 3.65% | 3.04% | 3.36% | -43.08% | |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 60Neutral | GBP 180.34M | -1.49 | -13.27% | ― | -4.98% | -43.98% | |
| 53Neutral | GBP 318.80M | 60.00 | 2.02% | 1.84% | 6.98% | -41.36% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VTXPF | Victrex plc | 12.28 | 4.62 | 60.25% | |
| GB:CRDA | Croda International | 3651.00 | 974.81 | 36.43% | |
| GB:ELM | Elementis plc | 194.00 | 37.93 | 24.30% | |
| GB:ESNT | Essentra plc | 114.00 | 22.91 | 25.16% | |
| GB:SYNT | Synthomer plc | 109.20 | 63.15 | 137.13% | |
| GB:ZTF | Zotefoams plc | 446.50 | 83.66 | 23.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.